143 related articles for article (PubMed ID: 37443517)
41. Preoperative thyroid-stimulating hormone associated risk of differentiated thyroid cancer in patients with thyroid nodules.
M AE
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):85-91. PubMed ID: 34933729
[TBL] [Abstract][Full Text] [Related]
42. [Value of VEGF-C, VEGF-D and VEGFR-3 levels combined with serum TSH in diagnosis of papillary thyroid carcinoma].
Huang J; Li Y; Xue G; Zhang W; Li S; Zhang J; Wu J
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1814-7, 1821. PubMed ID: 25537909
[TBL] [Abstract][Full Text] [Related]
43. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
44. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
45. Coexistence of Type-1 Diabetes Mellitus and Papillary Thyroid Carcinoma.
Calapkulu M; Sencar ME; Duger H; Bayram SM; Unsal IO; Cakal E; Ozbek M
Curr Diabetes Rev; 2020; 16(7):787-789. PubMed ID: 31686641
[TBL] [Abstract][Full Text] [Related]
46. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
47. Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis.
Lun Y; Wu X; Xia Q; Han Y; Zhang X; Liu Z; Wang F; Duan Z; Xin S; Zhang J
Otolaryngol Head Neck Surg; 2013 Mar; 148(3):396-402. PubMed ID: 23300224
[TBL] [Abstract][Full Text] [Related]
48. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean patients: a single-center experience.
Kim SS; Lee BJ; Lee JC; Song SH; Kim BH; Son SM; Kim IJ; Kim YK; Kang YH
Endocrine; 2011 Jun; 39(3):259-65. PubMed ID: 21161440
[TBL] [Abstract][Full Text] [Related]
49. Sensitivity to thyroid hormone indices are associated with papillary thyroid carcinoma in Chinese patients with thyroid nodules.
Sun J; Liu J; Wu TT; Gu ZY; Zhang XW
BMC Endocr Disord; 2023 Jun; 23(1):126. PubMed ID: 37264363
[TBL] [Abstract][Full Text] [Related]
50. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
51. Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients.
Liang J; Zeng W; Fang F; Yu T; Zhao Y; Fan X; Guo N; Gao X
Acta Otorhinolaryngol Ital; 2017 Oct; 37(5):393-400. PubMed ID: 29165434
[TBL] [Abstract][Full Text] [Related]
52. Hyperinsulinemia and thyroid peroxidase antibody in Chinese patients with papillary thyroid cancer.
Guo X; Chen X; Zhang C; Zhang J; Zhang C
Endocr J; 2019 Aug; 66(8):731-737. PubMed ID: 31118347
[TBL] [Abstract][Full Text] [Related]
53. Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in patients with indeterminate cytology.
Karatzas T; Vasileiadis I; Zapanti E; Charitoudis G; Karakostas E; Boutzios G
Am J Surg; 2016 Nov; 212(5):946-952. PubMed ID: 27324384
[TBL] [Abstract][Full Text] [Related]
54. A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review.
Yoon JH; Choi W; Park JY; Hong AR; Kim SS; Kim HK; Kang HC
BMC Endocr Disord; 2021 Aug; 21(1):177. PubMed ID: 34461869
[TBL] [Abstract][Full Text] [Related]
55. Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.
Dismukes J; Fazendin J; Obiarinze R; Márquez GCH; Ramonell KM; Buczek E; Lindeman B; Chen H
J Surg Res; 2021 Aug; 264():230-235. PubMed ID: 33838407
[TBL] [Abstract][Full Text] [Related]
56. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.
Huang H; Rusiecki J; Zhao N; Chen Y; Ma S; Yu H; Ward MH; Udelsman R; Zhang Y
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1209-1218. PubMed ID: 28377419
[No Abstract] [Full Text] [Related]
57. Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma?
Ma T; Wang H; Liu J; Zou J; Liu S
Front Endocrinol (Lausanne); 2021; 12():723631. PubMed ID: 34434171
[TBL] [Abstract][Full Text] [Related]
58. [Clinical and pathological differences between papillary thyroid carcinoma with Graves' disease and papillary thyroid carcinoma with Hashimoto's thyroiditis].
Xu DD; Lun Y; Liu X; Jiang H; Song JB; Duan ZQ; Xin SJ; Zhang J
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(32):2491-2495. PubMed ID: 28835054
[No Abstract] [Full Text] [Related]
59. The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer.
Lee IS; Hsieh AT; Lee TW; Lee TI; Chien YM
Int J Endocrinol; 2017; 2017():5940367. PubMed ID: 28951739
[TBL] [Abstract][Full Text] [Related]
60. Thyrotropin (TSH) and thyroid autoimmunity are predictive factors for the incidental discovery of papillary thyroid microcarcinoma during thyroidectomy.
Kyrilli A; Schoinochoriti R; Chatzopoulos V; Bahar N; Bouziotis J; D'Haene N; Salmon I; Ruiz M; Corvilain B
Endocrine; 2024 Jun; ():. PubMed ID: 38896365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
